Volume 72 • August 2011 • Number 8
1096 The Prevalence and Comorbidity of Social Anxiety Disorder Among United States Latinos: A Retrospective Analysis of Data From 2 National Surveys
Antonio J. Polo, Margarita Alegría, Chih-Nan Chen, and Carlos Blanco
[Abstract] [Full Text] [CME Activity] [Clinical Points]
- Although Latinos with social anxiety disorder (SAD) may have a later onset of the disorder than non-Latino whites, they may present with more impairment associated with the disorder across domains of functioning that include work, home, and social relationships.
- To better evaluate comorbidity among Latinos with SAD, consider a thorough assessment of other anxiety disorders, since those who arrive in the United States as adults may present with unique profiles that include a high risk of agoraphobia.
- Being fluent in English does not reduce the likelihood of having SAD among Latinos. In fact, those who grew up speaking both English and Spanish were at higher risk than those who grew up speaking primarily Spanish. Screening for SAD should be considered regardless of nativity.
[Close]
Original Research
1027 Clinical and Cognitive Correlates of Suicide Attempts in Bipolar Disorder: Is Suicide Predictable?
Alison M. Gilbert, Jessica L. Garno, Raphael J. Braga, Yaniv Shaya, Terry E. Goldberg, Anil K. Malhotra, and Katherine E. Burdick
[Abstract] [Full Text] [Clinical Points] [Supplementary Material]
- The study’s inability to find reliable neuropsychological predictors confirms the difficulty faced by clinicians in identifying which patients are at greatest risk for suicide attempt.
- Despite the failure to find reliable predictors of suicidal behavior, thorough clinical assessment of suicide risk by health care professionals continues to be essential.
[Close]
1034 The Impact of Changing Diagnostic Criteria in Posttraumatic Stress Disorder in a Canadian Epidemiologic Sample
Michael Van Ameringen, Catherine Mancini, and Beth Patterson
[Abstract] [Full Text] [Clinical Points]
- Since its inclusion in DSM-III, PTSD has undergone a number of changes in its diagnostic criteria, which have had a significant impact upon prevalence rates.
- Changes in PTSD diagnostic Criteria A to E do not appear to have as much influence on the rates of PTSD as does the addition of the Criterion F: clinically significant distress or impairment.
- This change has raised the diagnostic threshold for PTSD as demonstrated by lower prevalence rates.
- Moving toward DSM-5, the key issue appears to be how clinically significant distress and functional impairment should be defined.
[Close]
1042 “Extended” Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Gary Remington, Philip Seeman, Alan Feingold, Steve Mann, Chekkera Shammi, and Shitij Kapur
[Abstract] [Full Text] [Related Blog Post FREE to registered users]
1049 Childhood Trauma and Depressive Symptoms in Type 1 Diabetes
Alec Roy, Monique Roy, and David Goldman
[Abstract] [Full Text]
1054 The Efficacy of Omega-3 Supplementation for Major Depression: A Randomized Controlled Trial
François Lespérance, Nancy Frasure-Smith, Elise St-André, Gustavo Turecki, Paul Lespérance, and Stephen R. Wisniewski
[Abstract] [Full Text]
1072 PTSD Comorbidity and Suicidal Ideation Associated With PTSD Within the Ohio Army National Guard
Joseph R. Calabrese, Marta Prescott, Marijo Tamburrino, Israel Liberzon, Renee Slembarski, Emily Goldmann, Edwin Shirley, Thomas Fine, Toyomi Goto, Kimberly Wilson, Stephen Ganocy, Philip Chan, Mary Beth Serrano, James Sizemore, and Sandro Galea
[Abstract] [Full Text] [Clinical Points]
- When depression or alcohol dependence accompanies PTSD, view this clinical presentation as being accompanied by high risk for suicidality.
- Always look for co-occurring depression and alcohol dependence in PTSD.
- These 2 co-occurring illnesses increase the risk of suicidality more than 7-fold.
[Close]
1079 Risperidone Long-Acting Therapy Prescribing Patterns and Their Impact on Early Discontinuation of Treatment in a Large Medicaid Population
Timothy L. Boaz, Robert J. Constantine, John Robst, Marion A. Becker, and Andrew M. Howe
[Abstract] [Full Text]
1086 Efficacy and Safety of Duloxetine 60 mg and 120 mg Daily in Patients Hospitalized for Severe Depression: A Double-Blind Randomized Trial
Stephan Brecht, Durisala Desaiah, Elisete S. Marechal, Ambra M. Santini, Jana Podhorna, and Julien D. Guelfi
[Abstract] [Full Text]
1124 Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the Cerebrospinal Fluid of Civilians With Posttraumatic Stress Disorder Before and After Treatment With Paroxetine
Omer Bonne, Jessica Mary Gill, David A. Luckenbaugh, Carlos Collins, Michael J. Owens, Salvadore Alesci, Alexander Neumeister, Peixiong Yuan, Becky Kinkead, Huesseni K. Manji, Dennis S. Charney, and Meena Vythilingam
[Abstract] [Full Text]
Review Articles
1063 Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical Antipsychotics
Keming Gao, David E. Kemp, Elizabeth Fein, Zuowei Wang, Yiru Fang, Stephen J. Ganocy, and Joseph R. Calabrese
[Abstract] [Full Text]
1108 Relationship Between Daily Dose, Plasma Concentrations, Dopamine Receptor Occupancy, and Clinical Response to Quetiapine: A Review
Anna Sparshatt, David Taylor, Maxine X. Patel, and Shitij Kapur
[Abstract] [Full Text]
Early Career Psychiatrists
1129 Acupuncture for the Treatment of Major Depressive Disorder: A Randomized Controlled Trial
Carmen Andreescu, Ronald M. Glick, Chetachi A. Emeremni, Patricia R. Houck, and Benoit H. Mulsant
[Abstract] [Full Text]
1136 Measurement-Based Care in Psychiatric Practice: A Policy Framework for Implementation
Kelli Jane K. Harding, A. John Rush, Melissa Arbuckle, Madhukar H. Trivedi, and Harold Alan Pincus
[Abstract] [Full Text] [Related Blog Post FREE to registered users]
1144 Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: A Meta-Analysis of Placebo-Controlled Randomized Trials [Review]
Nadia Iovieno, Enrico Tedeschini, Kate H. Bentley, A. Eden Evins, and George I. Papakostas
[Abstract] [Full Text] [Clinical Points]
- Depression and alcohol use disorders often co-occur and may present diagnostic and management challenges.
- Current evidence supports the efficacy of antidepressants in treating depression in patients with comorbid alcohol abuse and/or dependence.
- Clinicians should consider the use of antidepressants as first-line therapy for targeting depressive symptoms in patients with unipolar depression and concurrent alcohol use.
[Close]
ASCP Corner
1152 Assessing the Adequacy of Past Antidepressant Trials: A Clinician’s Guide to the Antidepressant Treatment Response Questionnaire
Martin Desseilles, Janet Witte, Trina E. Chang, Nadia Iovieno, Christina M. Dording, Heidi Ashih, Maren Nyer, Marlene P. Freeman, Maurizio Fava, and David Mischoulon
[Purchase] [Full Text]
Letters to the Editor
1155 Treatment Outcome for Bereavement-Excluded Depression: Results of the Study by Corruble et al Are Not What They Seem
Jerome C. Wakefield and Michael B. First
[Purchase] [Full Text]
• Reply by Emmanuelle Corruble, Bruno Falissard, and Philip Gorwood
[Purchase] [Full Text]
1156 Searching For Serendipity
Samuel G. Siris
[Purchase] [Full Text]
• Reply by Andrew C. Leon
[Purchase] [Full Text]
1157 Corrections
Bennouna-Greene M, Frank J, Kremer S, Bursztejn C, Foucher J. Manic psychosis and auditory hallucinations following traumatic brain injury in a 13-year-old boy (J Clin Psychiatry 2010;71[4]:506–507)
de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine (J Clin Psychiatry 2009;70[10]:1416–1423)
Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LLL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. (J Clin Psychiatry 2009;70[11]:1540–1547)
Krystal AD, Harsh JR, Yang R, Rippon GA, Lankford DA. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression (J Clin Psychiatry 2010;71[1]:32–40)
Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia (J Clin Psychiatry 2008;69[5]:790–799)
[Purchase] [Full Text]
Book Reviews
1158 Long-Term Psychodynamic Psychotherapy: A Basic Text, 2nd ed
James J. Strain
[Purchase] [Full Text]
1158 Depression and Heart Disease
Melinda Randall
[Purchase] [Full Text]
1159 Introductory Textbook of Psychiatry, 5th ed
Thomas N. Wise
[Purchase] [Full Text]
1159 Depression and Diabetes
Frank W. Brown
[Purchase] [Full Text]
CME Activities
e25 Evidence for the Use of l-Methylfolate Combined With Antidepressants in MDD
Maurizio Fava, Richard C. Shelton, and John M. Zajecka
[Abstract]
e26 Safety and Tolerability of Antipsychotic Treatment in Young Patients With Schizophrenia
Christoph U. Correll
[Abstract]
e27 Selecting Appropriate Treatment for Patients Who Are Nonresponsive to Initial Therapy
J. Sloan Manning
[Abstract]
information for authors
see www.psychiatrist.com/author.htm
